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Abstract: Cartilage homeostasis is governed by articular chondrocytes via their ability to modulate
extracellular matrix production and degradation. In turn, chondrocyte activity is regulated by
growth factors such as those of the transforming growth factor β (TGFβ) family. Members of this
family include the TGFβs, bone morphogenetic proteins (BMPs), and growth and differentiation
factors (GDFs). Signaling by this protein family uniquely activates SMAD-dependent signaling and
transcription but also activates SMAD-independent signaling via MAPKs such as ERK and TAK1.
This review will address the pivotal role of the TGFβ family in cartilage biology by listing several
TGFβ family members and describing their signaling and importance for cartilage maintenance.
In addition, it is discussed how (pathological) processes such as aging, mechanical stress, and
inflammation contribute to altered TGFβ family signaling, leading to disturbed cartilage metabolism
and disease.
Keywords: transforming growth factor β; bone morphogenetic proteins; osteoarthritis; cartilage;
SMADs; aging; joint loading; inflammation; linker modifications
1. Introduction
The transforming growth factor β (TGFβ) family of polypeptide growth factors controls
development and homeostasis of many tissues, including articular cartilage. Articular cartilage
is the connective tissue covering joint surfaces and is a type of hyaline cartilage. This tissue is key in
facilitating movement with its smooth lubricated surface, and it functions as a shock absorber to disperse
forces acting upon movement with its physical properties. Articular cartilage is of mesodermal origin
and, remarkably for a tissue, is neither innervated nor does it contain blood vessels to supply oxygen
or nutrients [1,2]. The only cell type present in this tissue is the chondrocyte, which is surrounded by a
large amount (up to 98% of cartilage volume) of extracellular matrix (ECM) [1,3]. The ECM is a highly
organized network of hyaluronan, proteoglycans, and collagens. These collagens provide (tensile)
strength and shape to the tissue [4], and they mainly are (up to 90%) collagen type II (COL2A1) fibrils [5].
Hyaluronan is a glycosaminoglycan (GAG) (i.e., a long, unbranched polysaccharide), which forms
spontaneously aggregating networks to which other biomolecules such as proteoglycans can bind [6].
Proteoglycans are proteins glycosylated with sulfated GAGs. The most abundant proteoglycan (in
mass) in articular cartilage is aggrecan (ACAN), and this proteoglycan forms large aggregates with
hyaluronan. Because ACAN is heavily glycosylated with negatively charged sulfated GAGs, these
aggregates generate a (static) charge density. This charge density generates the force required to
counteract compressive forces during movement via attraction of solutes, which generate osmotic
swelling pressure, and via electrostatic repulsion if aggrecan molecules come in close proximity [7].
Articular cartilage is a highly structured tissue in which form fits function. Five distinct zones
can be observed: the lamina splendens, the superficial zone, the middle zone, the deep zone, and
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the calcified zone (Figure 1). The lamina splendens consists of collagen fibrils oriented in parallel to
the surface and high levels of hyaluronan and the lubricating proteoglycan lubricin (PRG4), but it
contains no cells [8–10]. These characteristics provide a smooth surface with a low friction coefficient.
Below the lamina splendens lies the superficial zone, which contains a relatively high number of
cells with flattened morphology oriented in parallel to the surface, which produce high amounts
of hyaluronan and PRG4 [8,10]. The collagen fibrils here are tightly packed and also oriented in
parallel to the surface. This orientation counteracts osmotic swelling pressure of the tissue below [9].
Beneath the superficial zone lies the middle zone, which represents 40%–60% of articular cartilage [2].
Chondrocytes in this zone are rounded but sparse. The collagen fibers are oriented isotropically to the
cartilage surface [9], which allows for efficient collapse of the tissue upon compression to dissipate the
energy of the impact. The collapse of this layer is accompanied by displacement and loss of water.
The more this layer is compacted, the more resistance to further collapse is increased [1]. This resistance
to further compression is due to an increase in electrostatic repulsion between proteoglycans and also
to an increase in hyaluronan viscosity because of an increase in concentration of this molecule [11].
Underneath the middle zone lies the deep zone (±30%). In the deep zone, chondrocytes are organized
in columns placed between collagen fibrils oriented perpendicular to the cartilage surface [6,9].
Furthermore, this zone contains relatively the highest levels of aggrecan of all zones [1]. The high levels
of aggrecan restrict water flow and thereby increase the compressive stiffness of cartilage. The collagen
fibers are oriented to withstand the swelling pressure generated by these proteoglycans and to
withstand sheer stresses generated by compression of the layers above. Part of the deep zone, below
the tidemark, contains calcium salts in the ECM and is, thus, called the calcified zone [2]. The calcified
zone forms the interface between bone and cartilage and anchors cartilage to the bone. This zone
contains hypertrophic-like chondrocytes which resemble chondrocytes undergoing endochondral
ossification [12].
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in anabolic (e.g., ECM production) and catabolic (e.g., ECM degradation) processes. Chondrocytes, 
as the only cell type present, are essential for balancing these processes. Therefore, chondrocyte 
metabolism is a key regulator of cartilage homeostasis and joint health. Many factors can regulate 
chondrocyte homeostasis, like hydrostatic pressure, tensile strain, and proinflammatory cytokines, 
but various growth factors, including those of the TGFβ family, play a key role in this. Growth factors 
modulate chondrocyte metabolism, differentiation, proliferation, and survival, and they regulate 
ECM production and turnover. This review will address the pivotal role of the TGFβ family in 
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Figure 1. Appearance and structure of adult (bovine) articular cartilage. Note that the orientation of
collagen fibrils differs per zone, from parallel in the superficial zone to perpendicular in the deep zone.
Scale bar = 100 µm.
The importance of articular cartilage for joint function is illustrated by the effects of its loss, which
leads to disability and pain, for example, in the word’s most common joint disease osteoarthritis
(OA). Degeneration and loss of articular cartilage are the consequence of an imbalance in anabolic
(e.g., ECM production) and catabolic (e.g., ECM degradation) processes. Chondrocytes, as the only
cell type present, are essential for balancing these processes. Therefore, chondrocyte metabolism is
a key regulator of cartilage homeostasis and joint health. Many factors can regulate chondrocyte
homeostasis, like hydrostatic pressure, tensile strain, and proinflammatory cytokines, but various
growth factors, including those of the TGFβ family, play a key role in this. Growth factors modulate
chondrocyte metabolism, differentiation, proliferation, and survival, and they regulate ECM production
and turnover. This review will address the pivotal role of the TGFβ family in chondrocyte (and thus
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cartilage) biology by listing several TGFβ family members and describing their importance. We will
discuss how these members signal and how this signaling impacts cartilage. Furthermore, we will
address how (pathological) processes such as aging, mechanical stress, and inflammation influence
TGFβ signaling in chondrocytes, leading to an altered metabolism and disease.
2. The Transforming Growth Factor B (TGFβ) Family and Its Signaling
The TGFβ family consists of over 30 members, including the TGFβs, activins, bone morphogenetic
proteins (BMPs), and growth/differentiation factors (GDFs). These factors share a characteristic
quaternary dimer structure [13] and signal via formation of heteromeric complexes between two types
(type I and type II) of serine threonine-protein kinase receptors [14].
There are seven type I and five type II receptors (Figure 2). Because every growth factor recruits a
specific, but not necessarily unique, receptor complex, this choice in receptors allows for differences in
growth factor sensitivity. In addition, multiple type III receptors have been characterized that facilitate
the interaction between ligand and receptor and can stabilize receptor complexes. For example, for
TGFβ betaglycan [15,16] and endoglin [17], and for BMPs the repulsive guidance molecule (RGM) family
members, RGM domain family member A (RGMA), dragon, and hemojuvelin have been identified
as co-receptors [18]. Also, inhibitory (pseudo) receptors have been identified, which bind ligands
but do not initiate signaling (e.g., CD109 for TGFβ signaling [19] and BMP and activin membrane
bound inhibitor (BAMBI) for BMP and activin signaling [20]). After formation of functional receptor
complexes, TGFβ family members can activate multiple intracellular signaling pathways, which are
categorized as either receptor SMAD (R-SMAD)-dependent or -independent, but R-SMAD-dependent
signaling is regarded as the unique and canonical signaling pathway of TGFβ family members.
2.1. R-SMAD-Dependent Signaling
R-SMADs are proteins approximately 50 kDa in size that, upon receptor-mediated activation
by carboxy terminal phosphorylation, migrate to the nucleus and function as transcription factors.
Two groups of R-SMADs can be distinguished based upon structural and functional homology: one
group consisting of SMAD1, SMAD5, and SMAD9 (also known as SMAD8) and one group containing
SMAD2 and SMAD3 [14]. Upon receptor type I activation, these R-SMADs are directly phosphorylated
on two serines at their C-terminal SXS motif. Specific ALKs phosphorylate specific SMADs: ALK1, 2,
3, and 6 phosphorylate SMAD1, 5, and 9, whereas ALK4, 5, and 7 phosphorylate SMAD2 and SMAD3.
This phosphorylation facilitates complexation of R-SMADs with the common SMAD (co-SMAD),
SMAD4, which promotes nuclear entry and accumulation. Inside the nucleus, this SMAD complex
directly binds DNA, although with low affinity, and recruits transcription factors for \high-affinity
interactions with DNA. The location where SMAD complexes bind DNA is dependent on characteristic
SMAD-binding motifs present in the DNA sequence, which differ for SMAD3/4 and SMAD1/5/9
(e.g., GTCTAGAC for SMAD2/3/4 complexes [21] and GCCGnCGC for SMAD1/5/9/4 complexes [22]).
Furthermore, the interaction between SMADs and DNA is regulated by the presence of master regulator
transcription factors [23]. Master regulators vary per tissue, and an important master regulator of
chondrocyte phenotype is SRY-box9 (SOX9), for example, which closely interacts with SMAD3/4 on the
collagen type II promotor [24].
Two important target genes of R-SMAD signaling are the inhibitory-SMADs (I-SMAD): SMAD6
and SMAD7 [25,26]. These I-SMADs function as inhibitors of R-SMAD signaling on multiple levels
by inhibiting C-terminal R-SMAD phosphorylation by inducing receptor dephosphorylation and
degradation, by inhibiting R-SMAD DNA binding, and by inhibiting complex formation between
SMAD4 and R-SMADs. In this way, SMAD6 predominantly inhibits SMAD1/5/9, and SMAD7
predominantly inhibits SMAD2/3 signaling, and both I-SMADs provide cells with an important
negative feedback mechanism to inactivate R-SMAD signaling.
A (simplified) overview of the SMAD-dependent signaling pathway is depicted in Figure 2.
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Figure 2. Transforming growth factor β (TGFβ) family SMAD-dependent signaling. Ligand binding
induces the formation of a receptor complex containing a type I and type II receptors. Type III receptors
stabilize and facilitate the binding of TGFβ to the receptor complex, which recruits a receptor SMAD
(R-SMAD). The R-SMAD is subsequently phosphorylated on its C-terminal domain, and a complex
is formed with the common SMAD4 (co-SMAD4). This complex translocates to the nucleus where it
can bind transcription factors, like SOX9 and RUNX2, and activates transcription. The activation of
SMAD2/3 signaling results in anti-hypertrophic and anti-inflammatory function, whereas activation of
SMAD1/5/9 signaling is associated with pro-hypertrophic regulation of the extracellular matrix and
maturation of the cartilage. Other important target genes are the inhibitory SMADs, SMAD6 and
SMAD7, whose expression provides the cell with a negative feedback mechanism. ACVR2 = Activin
type-2 receptor, ALK = ALK tyrosine kinase receptor, BMP = Bone morphogenetic protein, BMPR = Bone
orphogenetic protein receptor, GDF2 = Growth differentiation factor 2, MH(1/2) = MAD homology
(1/2) domain, RGM = Repulsive guidance olecule, RUNX2 = Runt-related transcription factor 2,
SOX9 = Transcription factor SOX9, TGFBR = TGFβ receptor
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2.2. SMAD-Dependent Signaling in Chondrocytes and Cartilage Biology
SMAD signaling is essential for the formation and maintenance of healthy cartilage. Both in vivo
and in vitro experiments point towards essential, but distinct, roles for SMAD2/3 versus SMAD1/5/9
signaling in chondrocyte biology.
In humans, genetic variation in SMAD3 is associated with hip and knee OA and total burden
of the disease [27,28]. Dominant nonsense, missense, or frameshift mutations in SMAD3 lead to
aneurysms-OA syndrome, a severe condition characterized by cardiovascular anomalies and early
onset of OA in multiple joints [29,30]. Mice with a Smad3 null mutation (Smad3∆exon8/∆exon8) develop
normal articular cartilage, but this starts to rapidly degrade one month after birth, resulting in severe
OA [31]. This rapid degradation is linked to an increased number of hypertrophic chondrocytes
present in both articular and epiphyseal cartilage [31]. These hypertrophic chondrocytes are unable
to maintain a healthy articular cartilage matrix and produce collagen type 10 (COL10A1) and matrix
metalloprotease 13 (MMP13), a potent cartilage-degrading enzyme. Increased chondrocyte hypertrophy
and accelerated cartilage degeneration are also observed in chondrocyte-specific Smad3-null mice
(Smad3∆exon2 + 3/∆exon2 + 3), which have been made using Col2-Cre and floxed Smad3 to circumvent
systemic effects of Smad3 deletion, confirming the direct role of SMAD3 in these processes [32]. In vitro
studies using overexpression or knockout of SMAD3 also support a role for SMAD3 in inhibiting
chondrocyte terminal differentiation, by showing an inhibitory or stimulating effect on chondrocyte
hypertrophy, respectively [33–36]. The anti-hypertrophic effect of SMAD3 is attributed to its interaction
with core-binding factor subunit α 1 (CBFA1), also known as runt-related transcription factor 2
(RUNX2) [32,37,38]. RUNX2 is a potent regulator of chondrocyte maturation [39]. For example,
overexpression of Runx2 in the murine teratoma-derived ATDC5 chondrocyte-like cell line induces
chondrocyte hypertrophy, whereas inhibition of RUNX2 achieves the opposite [32,38,40,41]. SMAD3
counteracts RUNX2 function by directly binding this transcription factor and recruiting silencing
histone class II deacetylases to RUNX2 responsive genes [37] such as MMP13, COL10A1, and alkaline
phosphatase (ALPL).
The role of SMAD2 in cartilage biology is less clear than that of SMAD3. In humans, there is
no known association between genetic variation in SMAD2 and OA. Smad2 knockout animals or
hypomorphs are not viable and die early during embryogenesis (≤embryonic day 9 [42–45]), before
the formation of articular joints [46], and are thus not usable to study the role of SMAD2 in articular
cartilage. Animals with only one genetic copy of Smad2 (Smad2+/−) can be viable [42,47], but no cartilage
phenotype has been reported. Cartilage-specific Smad2 knockout mice (Smad2fx/fx;Col2a1Cre) have
recently been studied [48], and such mice have an elongated hypertrophic zone in their growth plate.
This last observation indicates a similar anti-hypertrophic effect of SMAD2 as SMAD3. An in vitro
study supports a role for SMAD2 similar to that of SMAD3, because overexpression of a dominant
negative variant of Smad2 enhances, whereas overexpression of wildtype Smad2 protects against
chondrocyte hypertrophy, although less potent than SMAD3 [33].
SMAD1 and SMAD5 seem to have an important, but interchangeable, role in cartilage biology.
In contrast, SMAD9 seems to be of little importance for cartilage formation or maintenance. In humans,
no association has been reported between genetic variations in SMAD1, SMAD5, or SMAD9 and OA,
possibly due to redundant roles in cartilage. Like Smad2 knockout mice, Smad1 [49] or Smad5 [50]
knockout mice die before the formation of articular joints. Knockout of Smad9 is not embryonically
lethal yet does not seem to affect (epiphyseal) cartilage biology [51]. To study SMAD1 and SMAD5
in chondrogenesis, cartilage-specific knockouts have been made using Col2-cre and floxed Smad1 or
Smad5 [51]. Cartilage-specific removal of either Smad1 or Smad5 does not result in a phenotype, nor in
combination with whole body Smad9 knockout. Only when both Smad1 and Smad5 are ablated, severe
chondrodysplasia can be observed [51]. Additional removal of Smad9 does not add much to this severe
phenotype. Together, these observations indicate that SMAD1 and SMAD5 have an important, but
redundant, role in cartilage formation, whereas the role of SMAD9 seems limited [51]. The severe
chondrodysplasia is, in part, due to a lack of hypertrophic chondrocytes in the growth plates, suggesting
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that SMAD1/5 signaling regulates chondrocyte maturation. In vitro studies support a stimulatory
role of SMAD1/5 in chondrocyte maturation. For example, overexpression of Smad6, an inhibitor of
SMAD1/5/9, results in inhibited chondrogenesis in the ATDC5 cell line [52] and delayed chondrocyte
hypertrophy [53]. The stimulatory effects of SMAD1/5 on chondrocyte maturation most likely are
due to a stimulation of RUNX2 function. Such a stimulatory role of SMAD1/5 on RUNX2 function
has been described to be essential for BMP2-induced osteoblast differentiation [54–57]. Furthermore,
in pre-hypertrophic chondrocytes, SMAD1/5-RUNX2 interaction induces the activation of a reporter
construct based on the Col10a1 promoter, the expression of which is an important phenotypic marker
of hypertrophy [38,58]. How exactly SMAD1 and SMAD5 stimulate RUNX2 function is yet unclear.
2.3. SMAD-Independent Signaling
As mentioned, TGFβ family members can also activate R-SMAD-independent pathways.
Two examples are signaling via mitogen-activated protein kinase (MAPK) pathways involving
TGFβ-activated kinase 1 (TAK1) or extracellular signal-regulated kinase 1 and 2 (ERK1/2, also known
as MAPK3/1). The SMAD-independent signaling pathways are depicted in Figure 2. Of note, these
pathways are not unique for TGFβ family signaling but are important signaling mediators of many
other growth factors and cytokines as well.
Activation of MAPKs by TGFβ family members relies on adaptor proteins to bridge receptor activity
to pathway activation—for example, SHC adaptor protein 1 (SHC1) for ERK [59] and tumor necrosis
factor (TNF) receptor-associated factor 6 (TRAF6) for TAK1 activation [60,61]. Receptor-mediated
phosphorylation of SHC1 triggers a MAPK signaling cascade via GRB2/SOS, RAS, RAF, and MAP2K1,
resulting in activation of ERK1/2 [59]. TRAF6 is activated differently: upon receptor type I/type II
complex formation, TRAF6 oligomerization and auto-ubiquitination occurs, triggering complex
formation between TAK1 and TGFβ-activated kinase 1/MAP3K7 binding protein 1 (TAB1) via
poly-ubiquitination, which allows TAK1 auto-phosphorylation and activity [61]. Alternatively,
TAK1 can be activated by E3 ubiquitin-protein ligase XIAP (in complex with TAB1), the expression of
which is stabilized by interaction with BMP (and TGFβ) receptors [62,63]. Ultimately, activation of
MAPK signaling by TGFβ family members results in activation of JNK and p38 kinases, which directly
regulate gene expression by modulating transcription factors such as Jun proto-oncogene (c-JUN),
MYC proto-oncogene (c-MYC), activating transcription factor 2 (ATF2), and CCAAT/enhancer-binding
protein β (C/EBP-β) [64].
Both ERK and TAK1 contribute to TGFβ family signaling in chondrocytes. Functional inhibition
of ERK1 in ATDC5 cells via inhibition of its activating kinase MAP2K1 with the inhibitor U0126
reduces TGFβ-induced Acan expression [65]. Functional inhibition of ERK1 in rat chondrocytes
with the use of the MAP2K1 inhibitor PD98059 reduces TGFβ-induced proliferation and Acan and
Col2a1 expression [66,67]. Furthermore, in both human and bovine primary chondrocytes, use
of PD98059 lowers TGFβ-induced mRNA and protein expression of the metallopeptidase inhibitor
TIMP3 [68], indicating that ERK activity is a cartilage-protective component of TGFβ signaling in mature
chondrocytes. In contrast, during TGFβ-induced chondrogenesis in vitro, use of PD98059 increases
Col2a1 and Sox9 expression and proteoglycan synthesis in rat, chicken, and human mesenchymal
stem cells [69–71], indicating that ERK1/2 is an inhibitory component of TGFβ signaling during
TGFβ-induced chondrogenesis.
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Functional inhibition of TAK1 using a dominant negative form of Tak1 greatly diminishes the ability
of TGFβ and BMP2 to induce Col2a1 expression in rabbit articular chondrocytes [72]. In Col2-Cre;Tak1fl/fl
mice, Tak1 deletion in Col2a1-expressing cells during embryogenesis results in runting and severe
chondrodysplasia because of the reduced chondrocyte proliferation and delayed maturation [73], and
these mice die shortly before [73] or after birth [74]. This severe phenotype resembles the phenotype of
mice lacking BMP receptor/SMAD(1/5) signaling. Indeed, these mice show impaired BMP-induced
R-SMAD and p38 MAPK/JNK/ERK signaling [73,74], confirming that TAK1 is an important component
of BMP signaling in cartilage. Postnatal deletion of Tak1 using inducible Col2a1-CreERT2;Tak1fl/fl mice
also results in growth retardation, and these mice have profoundly decreased proteoglycan and
COL2A1 production in their articular cartilage [75]. This last observation shows that the importance of
TAK1 in cartilage biology is not limited to embryogenesis.
A possible role of TAK1 signaling in chondrocytes is the regulation of SOX9 production.
In chondrocytes, deletion of Tak1 inhibits endogenous and BMP2-induced Sox9 mRNA expression and
protein production, whereas overexpression of Tak1 enhances SOX9 levels [75]. This observation is
reflected in vivo: both articular and epiphyseal chondrocytes from Col2a1-CreERT2;Tak1fl/fl mice show
lower SOX9 protein production after deletion of Tak1 compared to control animals [75]. The induction
of Sox9 expression by TAK1 involves binding of activating transcription factor 2 (ATF2), a downstream
target of TAK1 via p38 MAPK, to the Sox9 promoter [75]. Furthermore, p38 MAPK signaling has also
been shown to stabilize SOX9 mRNA in human chondrocytes, further strengthening the importance of
this MAPK pathway in SOX9 regulation [76].
TGFβ family members can also signal via phosphoinositide 3-kinase (PI3K) or via the GTPase
RhoA [64], but it is unclear how and to what extent this occurs in chondrocytes. Activation of PI3Ks
leads to phosphorylation and activation of AKT serine/threonine kinase 1/2/3 (AKT1/2/3) and of
mechanistic target of rapamycin (MTOR) [77]. Recently, it has been shown that mechanistic target of
rapamycin complex 1 (mTORC1) activity is required for chondroblast growth and proliferation in
the epiphyseal plate of mice, but that its inactivation is required for chondrocyte differentiation [78].
In articular cartilage, MTOR is upregulated during OA [79] and is an inhibitor of chondroprotective
autophagy [79–81]. In vivo, intra-articular or intra-peritoneal injection of rapamycin (i.e., an inhibitor
of MTOR) increases autophagy and reduces cartilage damage in the DMM (surgical destabilization
of the medial meniscus) model of OA [80,81]. Furthermore, cartilage-specific Mtor knockout mice
(Col2-rt-TA-Cre; Mtorfl/fl) are protected against DMM-induced OA [79], confirming that MTOR signaling
is deleterious in OA conditions.
In chondrocytes, RhoA activates rho-associated coiled-coil containing protein kinase 1 (ROCK1) [82,83].
In primary human chondrocytes, ROCK inhibition induces SOX9, COL2A1, and ACAN mRNA
expressions [76], while in primary murine chondrocytes, ROCK inhibition enhances the output of
a SOX9-responsive luciferase assay along with Col2a1 and Acan mRNA expression [83]. Therefore,
these studies indicate a negative effect of RhoA/ROCK signaling on chondrocyte phenotype. However,
in murine mesenchymal cells during chondrogenic differentiation and chondrocytes cultured in 3D,
ROCK1 inhibition negatively affects SOX9 function [83]. This effect has been attributed to direct
phosphorylation of SOX9 by ROCK1, leading to nuclear accumulation and transcriptional activity
of SOX9 [84]; thus, in contrast to the previous studies, this indicates a positive effect of Rhoa/ROCK
signaling on chondrocyte phenotype.
A (simplified) overview of the SMAD-independent signaling pathways is depicted in Figure 3.
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Figure 3. Transforming growth factor β (TGFβ) family SMAD-independent signaling. Ligand binding
induces the formation of a receptor complex. This complex can initiate SMAD-independent signaling via
activation of adaptor proteins, e.g., SHC1 and TRAF6. This activation results in initiation of the ERK and
TAK signaling cascades, culminating in the activation of MAPKAPK2, p38, JNK, and NFκb. These pathways
induce transcription and tran lation and regulate diverse cellul r processes. AKT = RAC- lpha
serine/threonine-protein kinase, AP-1 = Activator protein 1, ATF2 = Cyclic AMP-dependent transcription
factor ATF-2, CEBPβ = CCAAT/enhancer-binding protein β, ERK = Mitogen-activated protein kinase 3,
GRB2 = Growth factor receptor-bound protein 2, HSP27 = Heat shock protein beta-1, IkBa = NF-kappa-B
inhibitor alpha, IKK = Inhibitor of nuclear factor kappa-B kinase, JNK = c-Jun N-terminal kinase, MAP2K
= Dual specificity mitogen-activated protein kinase kinase 1, MAPKAPK = MAP kinase-activated protein
kinase, MEF2 = Myocyte-specific enhancer factor 2A, MKK = Dual specificity mitogen-activated protein
kinase kinase, cMYC = Myc proto-oncogene protein, NEMO = NF-kappa-B essential modulator, NFκb
= nuclear factor kappa-light-chain-enhancer of activated B cells, p38 = p38 mitogen-activated protein
kinases, PI3K = Phosphatidylinositol 3-kinase, RAF = RAF proto-oncogene serine/threonine-protein
kinase, RAS = GTPase HRas, SHC1 = SHC-transforming protein 1, SOS = Son of sevenless homolog 1,
SP-1 = Sp1 transcription factor, TAB = TGF-beta-activated kinase 1 and MAP3K7-binding protein 1,
TAK1 = TGFβ-activated kinase 1, TCFs = ternary complex factors, TRAF6 = TNF receptor-associated
factor 6, and XIAP = E3 ubiquitin-protein ligase XIAP.
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3. TGFβ Family Members in Cartilage
3.1. TGFβ1, TGFβ2, and TGFβ3
The importance of TGFβ in cartilage biology was first observed in 1985 when two proteins were
extracted from bone that were capable of inducing chondrogenesis in rat embryonic mesenchymal
cells, and therefore were called cartilage inducing factor A and B [85]. Later research revealed that
these proteins were identical to TGFβ1 and TGFβ2 [86,87].
In mammals, three TGFβs exist—TGFβ1, TGFβ2, and TGFβ3—encoded by three different
genes—TGFB1, TGFB2 and TGFB3—and these homologs share a high percentage of amino acid
identity (71%–79%). All three TGFβs are produced in inactive forms as homodimers (or more rarely
as heterodimers [88]) bound by latency-associated peptide (LAP) and latent TGFβ binding protein
(LTBP) [89]. This production in the inactive form separates secretion from activity, an important concept
in TGFβ biology. All three forms of TGFβ are produced by chondrocytes [90–92] and a large amount
(60–200 ng/mL) of inactive TGFβ is bound to the ECM of cartilage [93,94]. Because TGFβ is produced
in the inactive form, activation is a crucial step in TGFβ signaling. For this, the noncovalent bond
between LAP and TGFβ has to be disrupted. This can occur enzymatically by degradation of LAP by,
for example, MMP3 [95], or nonenzymatically by a conformational change in the tertiary structure of
LAP. Shearing stress [96] or chemical modification of LAP by reactive oxygen species [97] can induce
such a conformational change. In addition, mechanical force as produced by compressive loading was
also shown to be an important physiological activator of ECM-bound TGFβ in cartilage [98].
In chondrocytes, TGFβ induces both SMAD2/3 and SMAD1/5/9-dependent signaling via ALK5
and ALK1, respectively, in addition to SMAD-independent signaling [99,100]. Which pathway is
activated by TGFβ depends on receptor level expression, co-receptor expression (i.e., endoglin enhances
signaling via ALK1), and dose of TGFβ. In chondrocytes, a low dose of TGFβ predominantly signals
via pSMAD2/3, whereas at high dosages, pSMAD1/5 signaling becomes more pronounced. Importantly,
both pathways have been described to antagonize each other in chondrocytes [99,100].
TGFβ signaling is associated with cartilage ECM production and maintenance. In mice, a
single intra-articular injection of rhTGFβ1 or rhTGFβ2 increases proteoglycan synthesis twofold
after four days, as measured by 35S-sulfate incorporation in patellar articular cartilage [101,102].
Also in vitro, TGFβ enhances proteoglycan production in both chondrocytes and cartilage explants
on both mRNA and protein level [103–106], together with production of other ECM components
like COL2A1 [106,107], cartilage oligomeric matrix protein (COMP) [108,109], perlecan [110],
fibronectin [111], and hyaluronan [112]. Furthermore, TGFβ is a potent inducer of lubricin (PRG4)
in chondrocytes [113], a key lubricating component of synovial fluid. However, in contrast to the
previously mentioned studies, inhibitory effects of TGFβ on chondrocyte proliferation, proteoglycan
synthesis, and COL2A1 production have also been described both in vitro and in vivo [107,114–119].
Possibly, different receptor signals play a role in these apparently contradictory observations.
Furthermore, TGFβ signaling has important anti-inflammatory effects in cartilage. TGFβ1
counteracts proinflammatory IL-1 signaling in vivo [120–122] and in vitro [123], and it helps cartilage
proteoglycan content recover after inflammation induced depletion [90,124]. How TGFβ exerts its
anti-inflammatory effects is not fully elucidated yet, but in primary rabbit articular chondrocytes, both
TGFβ1 and TGFβ3 downregulate IL-1 receptor (IL1R1) expression approximately 50% on protein
and mRNA level [123,125]. Furthermore, proinflammatory IL-6 signaling is also counteracted
by TGFβ by downregulation of IL-6 receptor levels in human and bovine chondrocytes [126].
In macrophages, TGFβ signaling can also stabilize NFκB inhibitor alpha (NFKBIA, also known
as IκBα), which is a potent inhibitor of NFκB, but this mechanism has not been described for
chondrocytes yet [127]. Another possible mechanism is the competition between SMAD3 and NFκB
for co-activating transcription factors like CREB binding protein, as has been described in endothelial
cells [128]. Additionally, many inflammatory genes counteracted by TGFβ contain both SMAD3 and
NFκb binding sites, leaving room for epigenetic regulation as a mechanism.
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An especially important role for TGFβ signaling lies in regulation of chondrocyte
hypertrophy. TGFβ-induced pSMAD2/3 signaling blocks hypertrophy and terminal differentiation
of chondrocytes [31,33,35,100,129]. In contrast, TGFβ-induced pSMAD1/5 via ALK1 is associated
with chondrocyte hypertrophy [99,100]. Both effects of TGFβ on hypertrophy can be observed
in vivo. Removal of TGFβ signaling in cartilage of two-week-old Col2-CreER;Tgfbr2flox/flox mice
results in an OA-like phenotype within 6 months via RUNX2-mediated Mmp13 and Adamts5
expression [130]. Furthermore, expression of a kinase-deficient dominant negative form of Tgfbr2 in
mice induces chondrocyte hypertrophy and osteoarthritis [131]. In contrast, removal of TGFβ signaling
in the hypertrophic chondrocytes of Col10a1-Cre;Tgfbr2flox/flox mice delays terminal differentiation
in the epiphyseal plate [132], and removal of TGFβ signaling in cartilage of eight-week-old
AgcCreERT2+/−;Tgfbr2flox/flox mice results in less hypertrophic chondrocytes after 12 months [133].
Because efficient removal of TGFBR2 was demonstrated in both the Col2-CreER;Tgfbr2flox/flox and
AgcCreERT2+/−;Tgfbr2flox/flox models, their different outcomes illustrate that age of TGFβ signaling
depletion (2 vs 8 weeks) and, thus, chondrocyte maturation status greatly affect the outcome and
impact of TGFβ signaling in chondrocytes.
Other family members which can induce (chondro-protective) SMAD2/3 signaling in chondrocytes
are the activins. However, little is known regarding their role and importance. Activin A, activin AB,
and activin B signal via ACVR2A/ACVR2B and ALK4/ALK7 to induce SMAD2/3 [134]. Expression of
the activin A subunit inhibin β A (INHBA) and activin A itself are upregulated in OA cartilage [135,136]
but also expression of its inhibitor follistatin is upregulated [137,138]. A possible role, which has
been demonstrated in vitro, is the inhibition of IL-1-induced ADAMTS4/5 activity [136], which would
indicate an anti-inflammatory role similar to the TGFβs. However, a lack of response of adult cartilage
tissue to activin A has been observed in multiple studies [109,139,140]; for example, activin A slightly
induces proteoglycan synthesis (i.e., 35S-incorporation) in immature (1–3 months old) but not in mature
(>18 months old) bovine articular cartilage explants [140]. Even less is known regarding the role in
cartilage of the activin antagonists, the inhibins, and only one study reports that inhibin inhibits both
proteoglycan synthesis (i.e., 35S-incorporation) and DNA synthesis in bovine chondrocytes [140], which
would indicate that activin signaling contributes to both these processes, again similar to the TGFβs.
3.2. Bone Morphogenetic Proteins (BMPs)
Multiple BMPs play an important role in chondrocyte biology, including BMP2, BMP7 (OP1),
BMP4, BMP6, BMP9 (GDF2), and BMP14 (GDF5) [141,142]. Chondrocytes express the BMP type I
receptors ALK1, ALK2, ALK3, and ALK6 and the type II receptors BMPR2, ACVR2A, and ACVR2B.
Genetic variation in either of these factors is not yet associated with OA. Like the TGFβs, BMPs are
produced as a dimer, but not only as homodimers; heterodimers of BMP2/6, BMP2/7, and BMP4/7
have been described both in vitro and in vivo [143]. In contrast to TGFβ activity, BMP activity is not
thought to be controlled via reassembly of BMPs with their prodomain to form a latency complex [143].
BMPs do reassemble with their prodomain to facilitate ECM binding, but this does not seem to confer
latency because it does not impair receptor type I and II binding [89,143,144]. Instead, antagonistic
scavenger proteins (e.g., gremlin, noggin, and sclerostin) and decoy receptors like BAMBI play an
important role in modulating BMP activity, all of which are produced by chondrocytes. Additionally,
BMPs can antagonize each other via competition for receptor type II binding [145].
In both healthy and OA cartilage, Bmp2 mRNA expression can be detected [146]. BMP2
signaling induces ECM production and proliferation. In ex vivo juvenile cartilage, BMP2 induces
proteoglycan content and COL2A1 production, as measured by 3H-proline incorporation assays [147],
whereas in vivo intra-articular injection of BMP2 in murine knee joints enhances proteoglycan
synthesis 2.5-fold (i.e., 35S-incorporation) in patellar cartilage within two days [102]. Furthermore,
intra-articular overexpression of BMP2 in the murine knee joint using adenoviruses also enhances
cartilage proteoglycan content [148]. In in vitro mesenchymal stromal cells and chondrocyte-like
cell lines, and in in vivo epiphyseal chondrocytes, BMP2 is a well-known inducer of chondrocyte
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maturation and hypertrophy [149]. However, in mice with cartilage-specific, tamoxifen-inducible
overexpression of BMP2 (Col2 rTA; TRE-Bmp2), increased hypertrophy is not observed in articular
cartilage after six weeks of prolonged exposure to tamoxifen [150]. Furthermore, in the DMM model
of experimental OA, the presence of excessive BMP2 signaling does not negatively, nor positively,
affect cartilage damage but does induce very extensive osteophyte formation [150]. These observations
might indicate that, in vivo, articular cartilage is not very sensitive to BMP2 signaling compared to
osteophyte-forming tissues like periosteum. Possibly, signaling of hyaluronan, an important structural
component of cartilage, via CD44 plays a role in this, as it has been demonstrated that this inhibits
BMP2-induced pSMAD1/5 signaling in the murine bone marrow-derived ST2 stromal cell line [151].
Alternatively, GDF5 has recently been shown to be a context-dependent inhibitor of BMP2 signaling,
via a yet unknown mechanism, possibly involving receptor competition [152], and GDF5 is present in
cartilage [153–155].
BMP7 mRNA and protein expression can be detected in both immature and mature articular
cartilage. Immunohistochemically, mature BMP7 can predominantly be detected in chondrocytes of
the superficial zone, whereas its pro-form is mainly detected in deep zone chondrocytes [156,157].
To signal, BMP7 can use ALK2, ALK3, and ALK6, and the type II receptors BMPR2, ACVR2A, and
ACVR2B, to induce SMAD1/5 phosphorylation and SMAD-independent signaling [143]. In contrast
to BMP2, a positive interaction of CD44 with BMP7 signaling has been described. Without CD44,
chondrocytes are not able to induce pSMAD1/5 in response to BMP7 [158–160]. In chondrocytes, BMP7
signaling induces ECM production. Both proteoglycan and COL2A1 production are induced in vitro in
juvenile and adult human primary chondrocytes [139] and ex vivo in juvenile bovine explants [147].
Furthermore, inhibition of endogenous BMP7 production with antisense oligonucleotides in cartilage
explants lowers aggrecan production [161]. In vitro, BMP7 also induces the expression of cartilage
oligomeric matrix protein [109] and hyaluronan synthase 2, resulting in more hyaluronan production
by chondrocytes, possibly facilitating deposition of aggrecan in the ECM [162]. In addition, BMP7 can
counteract an IL-1- or LPS-induced inhibition of proteoglycan synthesis in chondrocytes [163–165], and
partly inhibit IL-1-induced MMP13 expression, especially in the presence of IGF1 [166]. The positive
effects of BMP7 in vitro are reflected in vivo: conditional deletion of Bmp7 from limb mesenchyme in
Prx-Cre;Bmp7flox/flox mice results in proteoglycan loss (at 8 weeks old) and enhanced Mmp13 expression
(at 24 weeks old) [167]. Of note, joint and cartilage formation were not detectably affected in these
mice, but Bmp7 deletion did result in synovial inflammation, making it difficult to exclude indirect
effects. Administration of BMP7 is beneficial for cartilage in OA [168,169]. Osteoarthritic cartilage
is still responsive to BMP7 [155], and weekly injections of BMP7 diminish cartilage damage in the
rabbit ACLT model of OA [170]. Furthermore, BMP7 increases the quantity and quality of cartilage
repair tissue in rabbits with a full thickness cartilage defect [171]. Remarkably, although BMP7 can
induce ectopic bone formation [172], excessive osteophyte formation was not observed in these studies,
nor was excessive osteophyte formation observed in humans after a single injection of BMP7 in a
Phase 1 study done in symptomatic knee OA patients [173]. Although BMP7 induces SMAD1/5
phosphorylation, its signaling is not associated with chondrocyte hypertrophy. Bovine articular
chondrocytes do not undergo hypertrophy when cultured with BMP7 [174], and BMP7 blocks
hypertrophy in the ATDC5 cell line [175]. In long bone formation ex vivo, BMP7 does stimulate the
formation of pre-hypertrophic chondrocytes in the epiphyseal plate but blocks the transition towards
hypertrophy [176]. This anti-hypertrophic effect of BMP7 has contributed to its ability to induce the
transcription factor BAPX-1/NKX-3.2, a potent modulator of chondrocyte hypertrophy [177]. However,
BMP7 does induce ALPL activity and osteogenesis in primary fetal chondrocytes [178], and chick
sternum chondrocytes do undergo hypertrophy when cultured with BMP7 [179], indicating that BMP7
can induce chondrocyte hypertrophy, but, like TGFβ, it is in a context-dependent manner.
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Two other BMPs well known for their positive effect on chondrogenesis and cartilage formation are
BMP4 and BMP6, which both signal via ALK2 and ALK3 to induce pSMAD1/5 and SMAD-independent
signaling. However, very little is known regarding their role in mature articular cartilage. In bovine
chondrocytes and cartilage explants, BMP4 enhances proteoglycan synthesis, COL2A1 production,
and proliferation [140], and BMP4 has similar effects in human chondrocytes cultured in alginate [164].
BMP6 mRNA and protein are expressed in both healthy and OA articular cartilage [141]. In human
chondrocytes, BMP6 induces proteoglycan synthesis [164,180], but with advancing age, chondrocyte
response to BMP6 decreases [180]. However, in the epiphyseal plate, BMP6 is especially expressed in
the hypertrophic zone [181] where it has a stimulatory role on chondrocyte maturation. Furthermore,
a pro-hypertrophic effect of BMP6 has also been observed in ATDC5 cells [182]. These studies indicate
that BMP6 signaling could be detrimental for articular cartilage
A BMP that has more recently come to attention is BMP9, also known as GDF2. This BMP signals
via type II receptors ACVR2A/ACVR2B and BMPR2 and type I receptors ALK1, and/or ALK2 to
induce SMAD1/5 and SMAD-independent signaling. Production of BMP9 could not be detected in
chondrocytes [141], but BMP9 circulates in high levels in blood [183]. In juvenile bovine cartilage, BMP9
enhances the production of proteoglycans and does so more potently than BMP2 [147]. However, BMP9
can also induce ECM mineralization when chondrocytes are seeded in biodegradable polyglycolic acid
(PGA) scaffolds [184]. Additionally, also in mesenchymal progenitor cells, BMP9 is a potent inducer
of chondrogenesis accompanied by hypertrophy [185]. Therefore, BMP9 possibly has a detrimental
effect on chondrocyte homeostasis. Indeed, increased hypertrophy was observed in primary bovine
chondrocytes stimulated with this BMP, but remarkably, this was efficiently blocked via a synergy with
TGFβ1 on SMAD2/3 phosphorylation [186].
BMP14, better known as GDF5, is a very important initiator of joint formation and patterning.
The importance of GDF5 in cartilage biology is illustrated by the observations that mutations in GDF5
can lead to chondrodysplasias, and that a genetic SNP in the core promotor of GDF5, resulting in
reduced GDF5 protein levels, is associated with OA development [187]. However, regarding the role
of GDF5 in mature cartilage, relatively little is known. In chondrocytes, GDF5 predominantly signals
via ALK6 [178] but can also signal via ALK2 and ALK3 [152] to induce SMAD1/5 phosphorylation
and SMAD-independent signaling [188]. GDF5 is expressed in (im)mature cartilage, but its expression
is not affected by OA [141,154,155]. In cartilage, GDF5 induces proteoglycan synthesis [154,178] and
COMP expression [109] but neither COL2A1 synthesis nor chondrocyte proliferation [154]. Notably,
OA chondrocytes do not respond consistently to GDF5 [188]; that is, large variations can be observed
between OA patients on gene expression of targets like ACAN and SOX9 after addition of GDF5.
Possibly, a yet undiscovered co-receptor plays a role in this. Such a co-receptor has been postulated to
explain how GDF5 can function as a downstream BMP2 antagonist in ATDC5 cells even though it uses
the same type I and type II receptors [152]. Identification of such a co-receptor would greatly help
in understanding GDF5 signaling in chondrocytes and how it differs from BMP signaling using the
same receptors.
Figure 4 summarizes the effects of the different TGFβ family members on cartilage biology and
OA development.
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Figure 4. Effects of the different Transforming Growth Factor β (TGFβ) family members on articular
cartilage biology and osteoarthritis (OA) development. On the left healthy articular cartilage is depicted,
on the right osteoarthritic cartilage. The middle depicts how TGFβ family members regulate matrix
turnover, chondrocyte proliferation, hypertrophy-like differentiation, and inflammation. An imbalance
in these effects of TGFβ family members because of age- and/or inflammation-related changes contributes
to OA development. ADAMTS5 = A disintegrin and metalloproteinase with thrombospondin
motifs 5, ALPL = Alkaline phosphatase tissue-nonspecific isozyme, BAPX-1 = Homeobox protein
Nkx-3.2, BMP = Bone morphogenetic protein, GDF = Growth differentiation factor, IL = interleukin,
MMP = matrix metalloproteinase, NFκb = nuclear factor kappa-light-chain-enhancer of activated
B cells, PRG4 = proteoglycan 4, RUNX2 = Runt-related transcription factor 2, SOX9 = Transcription
factor SOX-9, and STAT3 = Signal transducer and activator of transcription 3.
4. Changes in TGFβ Family Signaling as Cause for Disease
4.1. Age-Related Changes in TGFβ S gnaling
In view of the aforementioned importance of TGFβ family members in chondrocyte and cartilage
homeostasis, it is not surprising that alterations in their signaling affect cartilage biology and can
lead to pathology. Alterations can occur because of various reasons, for example due to aging.
Aging affects TGFβ family signaling on multiple levels in the signaling cascade. For example,
ligand and receptor expression can be affected, just as intracellular signaling and regulation of gene
transcription [90,121,189–191].
Cells 2019, 8, 969 14 of 30
A prime example of how aging affects ligand expression is BMP7. In human cartilage, BMP7
gene and protein levels decline with advancing age. This decrease has been attributed to increased
methylation of its promoter, resulting in silencing of its expression [192,193]. In contrast, mRNA
expressions of BMP2, BMP6, and BMP9 do not seem to be affected by aging [141,146,156,190]. In mice,
protein expression levels of TGFβ2 and TGFβ3 (but not TGFβ1) decreased with age [90], whereas in
cows, a drop in Tgfb1 mRNA expression was observed [142].
Also, receptor expression is impacted by aging. Of type I receptors, a profound drop in ALK5
expression has been observed in humans, mice, guinea pigs, and cows on gene expression and
protein level [100,142,194], indicating that this occurs consistently across species. In addition, on gene
expression levels, loss of Alk2, Alk3, and Alk4 has also been observed in bovine cartilage [90,142].
Notably, loss of receptor expression can not only lead to loss of the growth factor response but also
alters the signaling of ligands able to use multiple receptors. For example, this has been demonstrated
for TGFβ signaling because aging affects Alk5 expression more than Alk1 expression, and TGFβ induces
relatively more SMAD1/5 phosphorylation in old cartilage, with all due effects [142,194]. Next to these
differences in type I receptor expression, an age-related decrease in Bmpr2 has also been observed [142].
This could possibly explain the age-related loss in the BMP7 response of chondrocytes that has been
observed [190]. However, how age-related changes affect BMP signaling (besides BMP7) in chondrocyte
homeostasis has not yet been sufficiently investigated.
Changes in receptor expression can affect intracellular signaling. As mentioned, an age-related
change in receptor type I expression towards relatively more ALK1 shifts the balance from protective
signaling (SMAD2/3) into deleterious signaling (SMAD1/5/9). The loss of protective SMAD2/3
signaling could explain the relation between aging and OA development [12,195]. Indeed, the changing
ALK1/ALK5 ratio in aging correlates with Mmp13 expression and OA development [89]. Computational
modeling supports a direct effect, especially TGFβ signaling via ALK1, which can explain Mmp13
expression and cartilage damage in aged cartilage [196]. Possibly, these effects run via decreased
modulation of RUNX2 activity. SMADs interact with RUNX2 to modulate chondrocyte differentiation,
where interaction of SMAD3 with RUNX2 inhibits RUNX2 functioning and SMAD1/5 stimulates
it [36,53,197,198].
4.2. Joint Loading-Related Changes in TGFβ Signaling
Next to aging, another factor able to modulate TGFβ family signaling is (mechanical) loading.
For example, mechanical joint loading has been shown to play a crucial role in activation of SMAD2/3
signaling [97,199,200]. In bovine articular cartilage explants, mechanical compression quickly induced
SMAD2/3 signaling, most likely due to mechanical activation of latent TGFβ bound to the ECM of
cartilage, as cartilage contains high levels of this. This loading-induced pSMAD2/3 signaling induced a
positive feedback loop, by stimulating expression of Tgfb1 and Alk5. In contrast, unloading rapidly
induced loss of SMAD2/3 signaling from articular cartilage (<2 h), possibly due to sequestering
of available TGFβ [201]. As a consequence of this, prolonged (2 weeks) unloading of cartilage
resulted in dramatically increased Col10a1 expression, a marker of chondrocyte hypertrophy. However,
repeated loading of cartilage every third day efficiently blocked this increase in Col10a1 expression.
These observations show the importance of cartilage loading for maintenance of SMAD2/3 signaling
and cartilage homeostasis. In view of the effects of SMAD3 signaling in cartilage, this mechanism
possibly also explains the observations that reduced joint loading contributes to cartilage degeneration
and production of the proteolytic enzymes MMP8 and MMP13 [202,203]. Importantly, old cartilage,
compared to young cartilage, has a strongly reduced capacity for this loading-mediated SMAD2/3
signaling, which possibly makes it more vulnerable to OA development [201,204]. Interestingly, a
sedentary lifestyle was recently hypothesized to be the cause for the doubled OA prevalence in current
populations compared to those from the 1800s to early 1900s after correction for age and BMI [205];
thus, possibly these observations are linked. Loading also induces BMP levels; BMP2, BMP4, BMP6,
and BMPR2 are increased by moderate exercise and suppresses post-traumatic OA [206]. However,
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excessive loading has been shown to lead to collagen damage, proteoglycan loss, and OA progression,
and these effects have been attributed to induction of gremlin-1, a BMP antagonist [207,208]. Together,
these studies show the impact of loading on TGFβ family signaling.
4.3. Inflammation-Related Changes in TGFβ Signaling
Previously, cartilage breakdown during OA was considered to be a simple wear and tear process.
However, nowadays, OA is regarded as a whole joint disease, with inflammation strongly implicated in
its pathogenesis [209,210]. In over 50% of patients, synovitis (i.e., inflammation of the synovium or joint
capsule) can be observed [211–217]. Important inflammatory mediators produced by this synovitis are
IL-1, TNF-α, IL-8, and IL-6 [210,218–221]. These pro-inflammatory cytokines have a direct effect on
cartilage homeostasis by upregulating MMPs and other cartilage-degrading enzymes [222–225] but,
importantly, also have been described to modulate TGFβ family signaling [226,227].
For example, IL-1 can downregulate TGFBR2 on mRNA and protein expression in human articular
chondrocytes [226]. Also, pro-inflammatory mediators produced by inflamed synovium, which was
cultured in vitro (OA synovium conditioned medium), reduced Tgfbr2 expression in mechanically
compressed bovine cartilage explants [228]. IL-1 has also been described to inhibit BMP7 signaling via
downregulation of the ALK2 and ALK3 receptors and inhibition of SMAD1 expression [229]. But in
contrast, IL-1 has also been described to induce BMP2 and BMP7 mRNA expression in chondrocytes,
and a high dose of IL-1 leads to the activation of pro-BMP7 into the active form [230].
Next to modulation of receptor expression, inflammatory mediators can also affect
SMAD-dependent signaling via various mechanisms. For instance, IL-1 can increase the expression of
i-SMAD7 via NF-κB activation in chondrocytes, which inhibits SMAD2/3 signaling [231]. Furthermore,
TNF-α and IL-1 have been described to be able to decrease DNA binding activity of SMAD3/4 complexes
in human OA chondrocytes via unknown mechanisms but independent of i-SMAD7 [227]. In addition,
inflammation-induced transcription factors can compete with SMADs for co-factors. For example,
SMAD3 and NFκB (a transcription factor downstream of TAK1) can compete for their common
co-transcription factor CREB binding protein (CBP) in endothelial cells [127].
Recent insights provided another way of how pro-inflammatory pathways can interact with
SMAD-dependent signaling, namely by post-translational modification of the linker region of
SMAD proteins [232,233]. SMAD proteins consist of a N-terminal MH1 (missing in i-SMAD6
and i-SMAD7), important for DNA binding activity and nuclear importation, and a C-terminal
MH2 domain, responsible for SMAD-receptor and SMAD–SMAD interactions and gene transcription
activation [234–237]. These two conserved MH1 and MH2 domains are connected via a regulatory linker
domain, which can be phosphorylated on specific serine and threonine residues. This phosphorylation of
the linker region regulates nuclear entry, SMAD–protein interactions, and SMAD turnover [232,238,239].
For instance, mutation of the SMAD3 linker resulted in strongly enhanced TGFβ-induced responses in
breast cancer cells and increased tumorigenesis during liver cancer [240,241]. Also, mutations in the
linker of SMAD4, commonly found in colorectal and pancreatic cancers, result in rapid proteasomal
degradation and loss of function [242,243]. These findings show that modification of the SMAD linkers
greatly affect SMAD function (Figure 3).
Phosphorylation of the serine and threonine residues in the linker domain is dependent on kinases,
including MAPKs, ERK, JNK, p38, AKT, CDKs, ROCK, and GSK-3 [233,238,239,244–246]. In addition,
dephosphorylation of the SMAD linker, dependent on phosphatases [237,247,248], is just as important
for regulating SMAD function. Notably, many of these kinases and phosphatases are induced in
chondrocytes by inflammatory mediators [222,249–252] present in the OA joint. This makes it likely
that inflammation-induced kinases can also affect SMAD function in cartilage, thereby affecting TGFβ
and BMP signaling and, thus, a possible cause for OA. Still, the relative importance of these SMAD
linker modifications in cartilage biology and OA pathogenesis is not well understood yet and warrants
further research.
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A (simplified) overview of SMAD modifications in the linker-domain that can alter TGFβ signaling
is depicted in Figure 5.
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5. Future Perspectives
In conclusion, members of the TGFβ family are crucial for the homeostasis of chondrocytes and,
thus, of cartilage. Signaling in cartilage goes via both SMAD-dependent and SMAD-independent
signaling, although both pathways are more integrated than their names suggest. Cellular context
plays a large role in TGFβ family signaling, greatly affecting its outcome, which is illustrated by,
for example, the differential effects of TGFβ and BMP7 in immature versus mature chondrocytes.
How aging or inflammation provide cellular context, which regulates TGFβ family signaling in articular
cartilage, is still largely unknown. Gaining greater insights into this would help to better understand OA
development and progression, and it would give leads for how to separate the beneficial effects of TGFβ
family members from their detrimental effects. This topic, thus, definitely warrants further research.
Of special interest might be the interaction of SMADs with other transcription factors. Such interactions
control (efficient) targeting and transcription of (potential) target genes. Altered interactions, for
example due to altered SMAD linker modifications, could explain context-dependent gain and loss of
function. How, for instance, the SMAD–RUNX2 interaction is affected by aging or inflammation could
be of great importance for cartilage degeneration. Closely related to this, it would be important to
further study other SMAD binding partners involved in regulating chondrocyte hypertrophy such as
myocyte enhancer-binding factor 2 (MEF2). This transcription factor has been shown to induce RUNX2
expression and hypertrophy in cartilage [253], and it has been described to interact and be inhibited
by SMAD3 in muscle cells [254,255]. Identifying such interactions in articular chondrocytes can help
us learn how cartilage degradation is regulated and would give leads on how to counteract this.
Another topic of interest is preventing the negative impact of processes such as inflammation on TGFβ
family signaling in cartilage. For this, a better understanding of the cellular processes driving these
negative effects is needed, but this hardly has been investigated until now. Especially, the relevance
of inflammation-driven SMAD linker post-translational modifications as causes for disturbed TGFβ
and BMP signaling warrants attention, because this possibly will provide a new avenue of targeted
Cells 2019, 8, 969 17 of 30
therapy directed at the inhibition of cartilage degradation in OA by targeting the intracellular kinases
and phosphatases responsible for these modifications.
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